

## Res. Asst. EFE CEM ERDAT

### Personal Information

Email: ecerdat@ankara.edu.tr  
Web: <https://avesis.ankara.edu.tr/ecerdat>

### International Researcher IDs

ORCID: 0000-0002-1250-1297  
Yoksis Researcher ID: 236091

### Education Information

Post Doctorate of Medicine, Ankara University, Ankara Tıp Fakültesi, Turkey 2021 - Continues  
Expertise In Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2015 - 2019  
Undergraduate, Hacettepe University, Tıp Fakültesi, Tıp Pr. (İngilizce), Turkey 2008 - 2014

### Foreign Languages

English, C1 Advanced  
German, A2 Elementary

### Certificates, Courses and Trainings

Data Analysis, Medical Statistics, Stanford University, 2020

### Dissertations

Expertise In Medicine, Lenfomalarda biyokimyasal belirteçlerin sistemik kemoterapiye tümör yanıtının değerlendirilmesinde kullanımı, Hacettepe University, 2019

### Academic Titles / Tasks

Research Assistant PhD, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2021 - Continues  
Research Assistant, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2015 - 2020

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. Comparison of the efficacy and safety of 3 months of CAPOX followed by 3 months of capecitabine and 6 months of CAPOX/FOLFOX in the adjuvant treatment of low-risk stage-III colon cancer treated surgically

Bardakci M., Esmer D., Hafizoglu E., Yaslikaya S., Genc T. B., Ozcelik M., ERDAT E. C., Hendem E., Buyukbayram M. E., ALACA TOPÇU Z., et al.

ONCOLOGY, no.11, pp.723-729, 2023 (SCI-Expanded)

**II. Biochemical Response Evaluation on Lymphomas: Proposing a Scoring System**

Erdat E. C.

UHOD - ULUSLARARASI HEMATOLOJI-ONKOLOJİ DERGİSİ, vol.33, no.3, pp.170-178, 2023 (SCI-Expanded)

**Articles Published in Other Journals**

**I. Enhancing the Anti-angiogenic Effect of Bevacizumab with ACE Inhibition on mCRC**

ERDAT E. C., KÖKSOY E. B., UTKAN G.

JOURNAL OF GASTROINTESTINAL CANCER, vol.54, no.3, pp.897-902, 2023 (ESCI)

**II. The evaluation of rheumatoid arthritis patients with knee and hip prosthesis: HURBIO biological registry**

ARMAĞAN B., ERDAT E. C., ERDEN A., SARI A., KALYONCU U., KİRAZ S., ERTEMLİ A. İ., KILIÇ L.

Ulusal Romatoloji Dergisi, vol.12, no.2, pp.39-44, 2020 (Peer-Reviewed Journal)

**Refereed Congress / Symposium Publications in Proceedings**

**I. Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results**

ARMAĞAN B., SARI A., ERDEN A., KILIÇ L., ERDAT E. C., KARADAĞ Ö., AKDOĞAN A., APRAŞ BİLGEN Ş. Ş., ERTEMLİ A. İ., KİRAZ S., et al.

2017 ACR/ARHP Annual Meeting, 3 - 08 November 2017

**II. THU0131 Premature coronary heart disease frequency in rheumatoid arthritis who are receiving biologic agents: hur-bio real life results**

ARMAĞAN B., SARI A., ERDEN A., KILIÇ L., ERDAT E. C., KARADAĞ Ö., AKDOĞAN A., APRAŞ BİLGEN Ş. Ş., KALYONCU U., KİRAZ S., et al.

EULAR 2017 ANNUAL MEETING, 14 - 17 June 2017

**III. AB0706 Ankylosing spondylitis patients with uveitis had better adalimumab retention rate: hur-bio real life results**

ARMAĞAN B., SARI A., ERDEN A., KILIÇ L., GÜVEN D. C., Pashayev T., BİLGİN E., ŞİMŞEK C., ERDAT E. C., KARADAĞ Ö., et al.

Abstracts Accepted for Publication, Madrid, Spain, 14 - 17 June 2017

**Metrics**

Publication: 8

Citation (WoS): 1

Citation (Scopus): 1

H-Index (WoS): 1

H-Index (Scopus): 1